The Lundbeck, Chiesi Group and Li-Cor Biosciences-backed eye and bladder cancer therapeutics developer has filed to go public on Nasdaq in an offering with a $100m placeholder target.

Aura Biosciences, a US-based cancer therapy developer backed by pharmaceutical firms Lundbeck and Chiesi Group and scientific measurement system provider Li-Cor Biosciences, has filed for an initial public offering. The IPO has a $100m placeholder figure and is set to take place on the Nasdaq Global Market. Cowen, SVB Leerink and Evercore are serving as…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.